Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Nagao, Yumiko ^a   Hashimoto, Kouji ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON; ITRACONAZOLE; MICONAZOLE; MICONAZOLE NITRATE; PEGINTERFERON; RIBAVIRIN; STEROID;

ADULT; ANGULAR CHEILITIS; APHTHOUS STOMATITIS; ARTICLE; BODY WEIGHT; CANDIDA ALBICANS; CANDIDIASIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; FUNGAL DETECTION; FUNGUS CULTURE; FUNGUS ISOLATION; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION RISK; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MOUTH LESION; MOUTH LICHEN PLANUS; NONHUMAN; ORAL MUCOSAL DISEASE; PREVALENCE; SALIVATION; SEROLOGY; TONGUE; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; CANDIDIASIS, ORAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RIBAVIRIN; SALIVARY GLANDS; SERUM ALBUMIN; STEROIDS; STOMATITIS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84868246059     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-155     Document Type: Article

References (46)

1. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-181.
2. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123:483-491. 10.1053/gast.2002.34785, 12145802.
3. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999, 30:653-659. 10.1016/S0168-8278(99)80196-2, 10207807.
4. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, . HCC Italian Task Force Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006, 44:1543-1554. 10.1002/hep.21415, 17133492, HCC Italian Task Force.
5. Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011, 204:84-93. 10.1093/infdis/jir210, 3307155, 21628662.
6. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, . PROVE1 Study Team Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838. 10.1056/NEJMoa0806104, 19403902, PROVE1 Study Team.
7. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995, 123:615-620.
8. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994, 19:841-848. 10.1002/hep.1840190407, 8138255.
9. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000, 79:47-56.
10. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002, 36:1439-1445.
11. Jubert C, Pawlotsky JM, Pouget F, Andre C, DeForges L, Bretagne S, Mavier JP, Duval J, Revuz J, Dhumeaux D, Bagot M. Lichen planus and hepatitis C virus-related chronic active hepatitis. Arch Dermatol 1994, 130:73-76. 10.1001/archderm.1994.01690010077011, 8285744.
12. Nagao Y, Sata M, Tanikawa K, Itoh K, Kameyama T. Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Invest 1995, 25:910-914. 10.1111/j.1365-2362.1995.tb01966.x, 8719930.
13. Carrozzo M, Gandolfo S, Carbone M, Colombatto P, Broccoletti R, Garzino-Demo P, Ghisetti V. Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case-control study. J Oral Pathol Med 1996, 25:527-533. 10.1111/j.1600-0714.1996.tb01726.x, 8986963.
14. Bagán JV, Ramón C, González L, Diago M, Milián MA, Cors R, Lloria E, Cardona F, Jiménez Y. Preliminary investigation of the association of oral lichen planus and hepatitis C. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85:532-536. 10.1016/S1079-2104(98)90286-4, 9619669.
15. Figueiredo LC, Carrilho FJ, de Andrage HF, Migliari DA. Oral lichen planus and hepatitis C virus infection. Oral Dis 2002, 8:42-46. 10.1034/j.1601-0825.2002.10763.x, 11939174.
16. Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 2: Lichen Planus and other diseases. Oral Dis 2008, 14:217-228. 10.1111/j.1601-0825.2007.01432.x, 18221456.
17. Nagao Y, Sata M, Ide T, Suzuki H, Tanikawa K, Itoh K, Kameyama T. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996, 26:1171-1174. 10.1046/j.1365-2362.1996.610607.x, 9013095.
18. Nagao Y, Sata M. Analysis of the factors motivating HCV-infected patients to accept interferon therapy. BMC Research Notes 2012, 5:470. 10.1186/1756-0500-5-470, 3500275, 22932002.
19. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002, 78:455-459. 10.1136/pmj.78.922.455, 1742467, 12185216.
20. Pankhurst CL. Candidiasis (oropharyngeal). Clin Evid 2006, 15:1849-1863.
21. Wilson J. The aetiology, diagnosis and management of denture stomatitis. Br Dent J 1998, 185:380-384. 10.1038/sj.bdj.4809821, 9828496.
22. Ellepola AN, Samaranayake LP. Antimycotic agents in oral candidosis: an overview: 1. Clinical variants. Dent Update 2000, 27:111-112. 114-116.
23. Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis 2005, 11:268-273. 10.1111/j.1601-0825.2005.01115.x, 16120112.
24. Krogh P, Holmstrup P, Thorn JJ, Vedtofte P, Pindborg JJ. Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol 1987, 63:48-54. 10.1016/0030-4220(87)90339-2, 3543797.
25. Jainkittivong A, Kuvatanasuchati J, Pipattanagovit P, Sinheng W. Candida in oral lichen planus patients undergoing topical steroid therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 104:61-66. 10.1016/j.tripleo.2006.10.024, 17261374.
26. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000, 7:211-217. 10.1046/j.1365-2893.2000.00215.x, 10849263.
27. Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis C patients. Hepat Mon 2011, 11:918-924. 3269061, 22308157.
28. Nagao Y, Sata M. Dental problems delaying the initiation of interferon therapy for HCV-infected patients. Virol J 2010, 7:192. 10.1186/1743-422X-7-192, 2933590, 20712912.
29. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000, 38:4171-4179. 87559, 11060086.
30. Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, Zadak M, Babiel R. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007, 38:326-333. 10.1016/j.jcv.2006.12.021, 17344093.
31. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994, 19:13-18. 10.1002/hep.1840190104, 8276349.
32. Zeng X, Hou X, Wang Z, Jiang L, Xiong C, Zhou M, Chen Q. Carriage rate and virulence attributes of oral Candida albicans isolates from patients with oral lichen planus: a study in an ethnic Chinese cohort. Mycoses 2009, 52:161-165. 10.1111/j.1439-0507.2008.01554.x, 18627473.
33. Coates EA, Brennan D, Logan RM, Goss AN, Scopacasa B, Spencer AJ, Gorkic E. Hepatitis C infection and associated oral health problems. Aust Dent J 2000, 45:108-114. 10.1111/j.1834-7819.2000.tb00249.x, 10925506.
34. Coates EA, Walsh L, Logan R. The increasing problem of hepatitis C virus infection. Aust Dent J 2001, 46:13-17. 10.1111/j.1834-7819.2001.tb00268.x, 11355234.
35. Henderson L, Muir M, Mills PR, Spence E, Fox R, McCruden EA, Bagg J. Oral health of patients with hepatitis C virus infection: a pilot study. Oral Dis 2001, 7:271-275. 10.1034/j.1601-0825.2001.00695.x, 12117200.
36. Griffin SO, Barker LK, Griffin PM, Cleveland JL, Kohn W. Oral health needs among adults in the United States with chronic diseases. J Am Dent Assoc 2009, 140:1266-1274.
37. Komaki N, Watanabe T, Ogasawara A, Sato N, Mikami T, Matsumoto T. Antifungal mechanism of hinokitiol against Candida albicans. Biol Pharm Bull 2008, 31:735-737. 10.1248/bpb.31.735, 18379073.
38. Nagao Y, Michio S. Effect of oral care gel on the quality of life for oral lichen planus in patients with chronic HCV infection. Virol J 2011, 8:348. 10.1186/1743-422X-8-348, 3149004, 21749712.
39. Back-Brito GN, da Mota AJ, de Souza Bernardes L, Takamune SS, Prado Ede F, Cordás TA, Balducci I, da Nobrega FG, Koga-Ito CY. Effects of eating disorders on oral fungal diversity. Oral Surg Oral Med Oral Pathol Oral Radiol 2012, 113:512-517.
40. Nagao Y, Sata M. Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J 2010, 7:375. 10.1186/1743-422X-7-375, 3022684, 21194423.
41. Nagao Y, Sata M. A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus. BMC Gastroenterol 2012, 12:31. 10.1186/1471-230X-12-31, 3364160, 22490000.
42. Nagao Y, Hanada S, Shishido S, Ide T, Kumashiro R, Ueno T, Sata M. Incidence of Sjögren's syndrome in Japanese patients with hepatitis C virus infection. J Gastroenterol Hepatol 2003, 18:258-266. 10.1046/j.1440-1746.2003.02982.x, 12603525.
43. Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. Oral Dis 2008, 14:123-130. 10.1111/j.1601-0825.2007.01436.x, 18208477.
44. Scully C, El-Kabir M, Samaranayake LP. Candida and oral candidosis: a review. Crit Rev Oral Biol Med 1994, 5:125-157.
45. Järvensivu A, Hietanen J, Rautemaa R, Sorsa T, Richardson M. Candida yeasts in chronic periodontitis tissues and subgingival microbial biofilms in vivo. Oral Dis 2004, 10:106-112. 10.1046/j.1354-523X.2003.00978.x, 14996281.
46. Ergun S, Cekici A, Topcuoglu N, Migliari DA, Külekçi G, Tanyeri H, Isik G. Oral status and Candida colonization in patients with Sjögren's Syndrome. Med Oral Patol Oral Cir Bucal 2010, 15:e310-e315.